EXHIBIT 12.1

	Ratio of Earnings to Fixed Charges
	(dollars in thousands, except ratio data)
	September 30,			December 31,			December 31,			December 31,			December 31,			December 31,
	2006 (5)			2005			2004			2003			2002			2001
Fixed Charges:
Interest expense on indebtedness (including amortization of debt expense and discount)	$	19,410		$	17,849		$	22,868		$	23,723		$	23,746		$	24,638
Interest expense on portion of rent expense representative of interest		14,731			14,614			9,089			7,604			7,206			6,159
Total Fixed Charges	$	34,141		$	32,463		$	31,957		$	31,327		$	30,952		$	30,797
Earnings (Loss):
Net loss before provision for income taxes	$	(184,229	)	$	(239,439	)	$	(242,898	)	$	(185,324	)	$	(219,716	)	$	(117,152	)
Fixed Charges per above		34,141			32,463			31,957			31,327			30,952			30,797
Total Earnings (Loss)	$	(150,088	)	$	(206,976	)	$	(210,941	)	$	(153,997	)	$	(188,764	)	$	(86,355	)
Ratio of Earnings to Fixed Charges		—			—			—			—			—			—
Coverage deficiency (1)(2)(3)(4)	$	(184,229	)	$	(239,439	)	$	(242,898	)	$	(185,324	)	$	(219,716	)	$	(117,152	)

(1)	The Company’s Coverage deficiency for 2006 includes a charge of $16,840 relating to lease termination costs associated with one of the Company’s facilities.
(2)	The Company’s Coverage deficiency for 2004 includes net charges of $12,975, relating to a $15,408 charge for restructuring partially offset by a gain recognized on the extinguishment of debt of $2,433.
(3)	The Company’s Coverage deficiency for 2002 includes charges aggregating $46,396 arising from the Company’s impairment charge relating to its investment in CAT and a charge for construction design changes of $32,158 and $14,238, respectively.
(4)	The Company’s Coverage deficiency for 2001 includes charges aggregating $26,208 arising from the Company’s impairment charge relating to its investment in Transgene and debt conversion expenses of $22,314 and $3,894, respectively.
(5)	Amounts presented are for the nine months ended September 30, 2006.